NeoImmuneTech, Inc.

Equities

A950220

KR8840140006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1,651 ^KRW	+17.93%		+17.09%	-18.47%

Apr. 02	NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	CI
Jan. 15	NeoImmuneTech, Inc. Appoints Luke Oh as President	CI

An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.

November 24, 2021

An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. (KOSDAQ:A950220) from SillaJen, Inc. (KOSDAQ:A215600) for KRW 10.1 billion on November 25, 2021. Under the transaction, SillaJen to sell 1 million shares of NeoImmuneTech for a consideration to be received in cash. Transaction is expected to complete on November 25, 2021.

Latest news about NeoImmuneTech, Inc.

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes	Apr. 02	CI
NeoImmuneTech, Inc. Appoints Luke Oh as President	Jan. 15	CI
Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome	Nov. 20	CI
Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board	23-07-26	CI
NeoImmuneTech, Inc. to Partner with U.S. National Institute of Allergy and Infectious Diseases, National Institutes of Health for Drug Development in Acute Radiation Syndrome	23-01-03	CI
New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors	22-11-11	CI
NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board	22-08-08	CI
NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity	22-06-14	CI
NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors	22-06-06	CI
Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022	22-04-13	CI
NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers	22-02-07	CI
NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7	22-01-24	CI
South Korea's Secondary Stock Market Adds Largest Number of New Tech IPOs in 2021	21-12-28	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	21-11-24	CI
NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global Technology, Inc.	21-11-24	CI
NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting	21-11-22	CI
NeoImmuneTech, Inc. Presents Data in Three Posters At Society for Immunotherapy of Cancer Annual Meeting	21-11-16	CI
NeoimmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (Efineptakin Alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer	21-11-08	CI
NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma	21-10-13	CI
NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting	21-10-04	CI
NeoImmuneTech, Inc.(KOSDAQ:A950220) added to S&P Global BMI Index	21-09-20	CI
Neoimmunetech to Present At Society for Neuro-Oncology	21-09-13	CI
NeoImmuneTech, Inc. Appoints Jean Fan, M.D., as Chief Clinical Officer	21-08-25	CI
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection	21-07-26	CI
NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo®	21-06-08	CI

Chart NeoImmuneTech, Inc.

Duration

Period

More charts

Company Profile

NeoImmuneTech, Inc. is a clinical-stage T cell-focused biopharmaceutical company. The Company is engaged in the discovery and development of immuno-therapeutics. Its lead asset includes NT-I7 (efineptakin alfa), which is a T Cell Amplifier. NT-I7 is a human IL-7 (Interleukin-7) fusion protein that overcomes the limitations of endogenous IL-7. The IL-7 domain promotes T cell development, which plays a role in the immune response. The N-terminus of the IL-7 domain overcomes its structural instability and enables mass production of NT-I7. NT-I7 is a clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications. It is conducting multiple clinical trials of NT-I7 in multiple indications both as a monotherapy and in combination with other therapeutics, such as checkpoint inhibitors and other. Its products include NIT-106, NIT-109, NIT-110, NIT-119, NIT-120, NIT-104, NIT-107, NIT-112, NIT-105, NIT-108, NIT-113, NIT-114, NIT-115, NIT-116 and NIT-A01.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEOIMMUNETECH, INC.	-18.47%	20.12M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs